首页> 外文期刊>Antimicrobial agents and chemotherapy. >Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family
【24h】

Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family

机译:22种抗结核药物对SLC22A族有机阴离子和阳离子转运蛋白的抑制性相互作用潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Twenty-two currently marketed antituberculosis drugs were comprehensively evaluated for their inhibitory effect on organic anionic transporter (OAT)-and organic cation transporter (OCT)-mediated uptake using stably transfected HEK293 cells in vitro. We observed moderate to strong inhibitory effects on OAT1-and OAT3-mediated para-aminohippurate (PAH) uptake and OCT1- and OCT2-mediated N-methyl-4-phenylpylidinium acetate (MPP+) uptake. Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC(50)s) being 35.1, 31.1, 37.6, and 48.1 mu M, respectively, for OAT1 and> 100, 21.9, 24.6, and 30.2 mu M, respectively, for OAT3. Similarly, pyrazinamide, rifabutin, and levofloxacin were observed to have inhibitory effects, with IC50 values being 36.5, 42.7, and 30.3 mu M, respectively, for OCT1 and with the IC50 value for PAS being 94.2 mu M for OCT2. In addition, we used zidovudine and metformin as clinically prescribed substrates of OATs and OCTs, respectively, and zidovudine and metformin uptake was also strongly inhibited by the antituberculosis drugs. Among the tested drugs, the highest drug-drug interaction (DDI) indexes were found for PAS, which were 9.3 to 13.9 for OAT1 and 12.0 to 17.7 for OAT3, and linezolid, which were 1.18 to 2.15 for OAT1 and 1.7 to 3.01 for OAT3. Similarly, the DDI indexes of pyrazinamide and levofloxacin were 0.57 and 0.30, respectively, for OCT1, and the DDI index of PAS was 3.8 for OCT2, suggesting a stronger possibility (DDI index value cutoff, >0.1) of in vivo DDIs. This is the first comprehensive report of the inhibitory potential of anti-TB drugs on OAT- and OCT-mediated uptake of prototype and clinically prescribed substrate drugs in vitro, providing an ability to predict DDIs between anti-TB drugs and other coprescribed drugs in clinical studies in vivo.
机译:使用体外稳定转染的HEK293细胞,对目前市售的22种抗结核药物对有机阴离子转运蛋白(OAT)和有机阳离子转运蛋白(OCT)介导的摄取的抑制作用进行了全面评估。我们观察到对OAT1和OAT3介导的对氨基马尿酸盐(PAH)摄取以及OCT1和OCT2介导的N-甲基-4-苯基吡啶鎓乙酸盐(MPP +)摄取的中度至强抑制作用。观察到环丙沙星,利奈唑胺,对氨基水杨酸(PAS)和利福平具有强抑制作用,对50%抑制作用的浓度(IC(50)s为35.1、31.1、37.6和48.1μM,对于OAT1分别为100和21.9、24.6和30.2μM,对于OAT3。同样,观察到吡嗪酰胺,利福布汀和左氧氟沙星具有抑制作用,OCT1的IC50值分别为36.5、42.7和30.3μM,而OCT2的PAS的IC50值为94.2μM。此外,我们分别使用齐多夫定和二甲双胍作为临床上规定的OAT和OCT底物,并且抗结核药物也强烈抑制了齐多夫定和二甲双胍的摄取。在所测试的药物中,发现PAS的最高药物相互作用指数(DDI)为OAT1 9.3至13.9,OAT3 12.0至17.7,利奈唑胺,OAT1为1.18至2.15,OAT3为1.7至3.01 。同样,对于OCT1,吡嗪酰胺和左氧氟沙星的DDI指数分别为0.57和0.30,对于OCT2,PAS的DDI指数为3.8,表明体内DDI的可能性更大(DDI指数值截止,> 0.1)。这是关于抗结核药对OAT和OCT介导的原型和临床规定的底物药物体外吸收的抑制潜力的首份综合报告,提供了预测临床中抗结核药与其他共同处方药之间DDI的能力体内研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号